Oritavancin: A Review in Acute Bacterial Skin and Skin Structure Infections-Reference-Cited by-同舟云学术

Oritavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

Published:2015-10-13 Issue:16 Volume:75 Page:1891-1902
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Syed Yahiya Y.,Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0478-7.pdf

Reference73 articles.

1. US FDA. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. http://www.fda.gov/ . Accessed 25 Jun 2015.

2. Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377–85.

3. Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–19.

4. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147–59.

5. Khachatryan A, Patel D, Stephens J, et al. Rising US hospital admissions for Gram+ acute bacterial skin and skin structure infections (ABSSSI) [abstract no. 58]. J Hosp Med. 2014;9(Suppl 2).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians;Pharmaceuticals;2023-09-15

2. Design Methods for Antimicrobial Peptides with Improved Performance;Zoological Research;2023

3. Pharmacokinetics and pharmacodynamics of peptide antibiotics;Advanced Drug Delivery Reviews;2022-04

4. Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA;Drugs & Therapy Perspectives;2022-02

5. Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis;Infectious Diseases in Clinical Practice;2021-12-28